市場調査レポート

商品コード

1317692

直接作用型抗ウイルス薬市場：タイプ別、適応症別、ルート別、流通チャネル別-2023～2030年の世界予測

Direct-acting Antiviral Drug Market by Type, Indication, Route, Distribution Channel - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

出版日: 2023年06月12日 | 発行: 360iResearch

| ページ情報: 英文 189 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF, Excel & Online Access - 1 Year (Single User License)

USD 4,749 744,453円

レポートPDF及びExcelを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

PDF, Excel & Online Access - 1 Year (Up to 5 User License)

USD 5,749 901,213円

レポートPDF及びExcelを5名まで共有ご利用頂けるライセンスです。ご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

PDF, Excel & Online Access - 1 Year (Site License)

USD 6,749 1,057,973円

レポートPDF及びExcelを同一事業所（所在地）内のすべての方でご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

PDF, Excel & Online Access - 1 Year (Enterprise User License)

USD 8,749 1,371,493円

レポートPDF及びExcelを同一企業の全世界の方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

ご注意事項 :

本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

直接作用型抗ウイルス薬の世界市場は、2023年に107億1,662万米ドル、CAGR13.41％で大きく成長し、2030年には257億6,287万米ドルに達すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界の直接作用型抗ウイルス薬市場を評価するために不可欠です。事業戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.直接作用型抗ウイルス薬の世界市場規模および予測は？

2.予測期間中、世界の直接作用型抗ウイルス薬市場を形成するCOVID-19の阻害要因と影響は？

3.直接作用型抗ウイルス薬の世界市場において予測期間中に投資すべき製品/セグメント/用途/分野は？

4.直接作用型抗ウイルス薬の世界市場における競争戦略は？

5.直接作用型抗ウイルス薬の世界市場における技術動向と規制の枠組みは？

6.直接作用型抗ウイルス薬の世界市場における主要ベンダーの市場シェアは？

7.直接作用型抗ウイルス薬の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

市場力学
- 促進要因
  - 肝細胞がんと肝硬変の有病率と発生率の増加
  - 新しい直接作用型抗ウイルス薬の製品開発と上市の増加
  - 新興国における意識の向上とヘルスケアインフラの改善
- 抑制要因
  - 直接作用型抗ウイルス薬は高価
- 機会
  - 直接作用型抗ウイルス薬に対する政府当局や社会ヘルスケア協会からの支援の増加
  - 直接作用型抗ウイルス薬の入手可能性と組織間の戦略的連携
- 課題
  - ブランドの直接作用型抗ウイルス薬の特許失効
市場動向
COVID-19の累積的な影響
ロシア・ウクライナ紛争の累積的影響
高インフレの累積的影響
ポーターのファイブフォース分析
バリューチェーンとクリティカルパス分析
規制の枠組み
顧客のカスタマイズ

第6章直接作用型抗ウイルス薬市場：タイプ別

イントロダクション
NS3/4Aプロテアーゼ
NS5Aタンパク質
NS5B RNA依存性RNAポリメラーゼ

第7章直接作用型抗ウイルス薬市場：適応症別

イントロダクション
C型肝炎ウイルス
HIV感染症/エイズ
インフルエンザ
予防

第8章直接作用型抗ウイルス薬市場：投与経路別

イントロダクション
静脈内
経口
皮下
局所

第9章直接作用型抗ウイルス薬市場：流通チャネル別

イントロダクション
病院薬局
オンラインドラッグストア
小売薬局

第10章南北アメリカの直接作用型抗ウイルス薬市場

イントロダクション
アルゼンチン
ブラジル
カナダ
メキシコ
米国

第11章アジア太平洋地域の直接作用型抗ウイルス薬市場

イントロダクション
オーストラリア
中国
インド
インドネシア
日本
マレーシア
フィリピン
シンガポール
韓国
台湾
タイ
ベトナム

第12章欧州・中東・アフリカの直接作用型抗ウイルス薬市場

イントロダクション
デンマーク
エジプト
フィンランド
フランス
ドイツ
イスラエル
イタリア
オランダ
ナイジェリア
ノルウェー
ポーランド
カタール
ロシア
サウジアラビア
南アフリカ
スペイン
スウェーデン
スイス
トルコ
アラブ首長国連邦
英国

第13章競合情勢

FPNVポジショニングマトリクス
市場シェア分析：主要企業別
競合シナリオ分析：主要企業別

第14章掲載企業一覧

第15章付録

ディスカッションガイド
ライセンスと価格について

図表

LIST OF FIGURES

FIGURE 1. DIRECT-ACTING ANTIVIRAL DRUG MARKET RESEARCH PROCESS
FIGURE 2. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2022 VS 2030
FIGURE 3. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
FIGURE 5. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2022 VS 2030 (%)
FIGURE 6. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2022 VS 2030 (%)
FIGURE 7. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
FIGURE 8. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 9. DIRECT-ACTING ANTIVIRAL DRUG MARKET DYNAMICS
FIGURE 10. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 12. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 13. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 18. DIRECT-ACTING ANTIVIRAL DRUG MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 19. DIRECT-ACTING ANTIVIRAL DRUG MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

TABLE 1. DIRECT-ACTING ANTIVIRAL DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 5. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS3/4A PROTEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 6. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5A PROTEIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5B RNA-DEPENDENT RNA POLYMERASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 9. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV INFECTION/ AIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 14. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 19. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ONLINE DRUG STORE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 27. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 28. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 29. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 30. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 31. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 32. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 33. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 34. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 35. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 36. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 37. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 38. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 39. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 40. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 41. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 42. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 48. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 49. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 50. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 51. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 52. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 54. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 55. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 56. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 58. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 59. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 60. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 61. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 62. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 63. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 64. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 66. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 67. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 68. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 70. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 71. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 72. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 74. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 75. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 76. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 78. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 79. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 80. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. SINGAPORE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 82. SINGAPORE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 83. SINGAPORE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 84. SINGAPORE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 86. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 87. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 88. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. TAIWAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 90. TAIWAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 91. TAIWAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 92. TAIWAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 93. THAILAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 94. THAILAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 95. THAILAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 96. THAILAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. VIETNAM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 98. VIETNAM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 99. VIETNAM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 100. VIETNAM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. DENMARK DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 107. DENMARK DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 108. DENMARK DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 109. DENMARK DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. EGYPT DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 111. EGYPT DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 112. EGYPT DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 113. EGYPT DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. FINLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 115. FINLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 116. FINLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 117. FINLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 119. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 120. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 121. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 123. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 124. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 125. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. ISRAEL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 127. ISRAEL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 128. ISRAEL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 129. ISRAEL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 131. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 132. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 133. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. NETHERLANDS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 135. NETHERLANDS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 136. NETHERLANDS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 137. NETHERLANDS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. NIGERIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 139. NIGERIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 140. NIGERIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 141. NIGERIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. NORWAY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 143. NORWAY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 144. NORWAY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 145. NORWAY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. POLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 147. POLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 148. POLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 149. POLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. QATAR DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 151. QATAR DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 152. QATAR DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 153. QATAR DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 167. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 168. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 169. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. SWEDEN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 171. SWEDEN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 172. SWEDEN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 173. SWEDEN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. SWITZERLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 175. SWITZERLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 176. SWITZERLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 177. SWITZERLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. TURKEY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 179. TURKEY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 180. TURKEY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 181. TURKEY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 188. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 190. DIRECT-ACTING ANTIVIRAL DRUG MARKET, FPNV POSITIONING MATRIX, 2022
TABLE 191. DIRECT-ACTING ANTIVIRAL DRUG MARKET SHARE, BY KEY PLAYER, 2022
TABLE 192. DIRECT-ACTING ANTIVIRAL DRUG MARKET LICENSE & PRICING

Product Code: MRR-032A67D91461

The Global Direct-acting Antiviral Drug Market is forecasted to grow significantly, with a projected USD 10,716.62 million in 2023 at a CAGR of 13.41% and expected to reach a staggering USD 25,762.87 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Direct-acting Antiviral Drug Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Direct-acting Antiviral Drug Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Type, market is studied across NS3/4A Protease, NS5A Protein, and NS5B RNA-Dependent RNA polymerase. The NS3/4A Protease is projected to witness significant market share during forecast period.

Based on Indication, market is studied across Hepatitis C Virus, HIV Infection/ AIDS, Influenza, and Prophylaxis. The Influenza is projected to witness significant market share during forecast period.

Based on Route, market is studied across Intravenous, Oral, Subcutaneous, and Topical. The Subcutaneous is projected to witness significant market share during forecast period.

Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Drug Store, and Retail Pharmacy. The Online Drug Store is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded largest market share of 36.70% in 2022, followed by Americas.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Direct-acting Antiviral Drug Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Direct-acting Antiviral Drug Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Direct-acting Antiviral Drug Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Direct-acting Antiviral Drug Market?

4. What is the competitive strategic window for opportunities in the Global Direct-acting Antiviral Drug Market?

5. What are the technology trends and regulatory frameworks in the Global Direct-acting Antiviral Drug Market?

6. What is the market share of the leading vendors in the Global Direct-acting Antiviral Drug Market?

7. What modes and strategic moves are considered suitable for entering the Global Direct-acting Antiviral Drug Market?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Direct-acting Antiviral Drug Market, by Type, 2022 vs 2030
4.3. Direct-acting Antiviral Drug Market, by Indication, 2022 vs 2030
4.4. Direct-acting Antiviral Drug Market, by Route, 2022 vs 2030
4.5. Direct-acting Antiviral Drug Market, by Distribution Channel, 2022 vs 2030
4.6. Direct-acting Antiviral Drug Market, by Region, 2022 vs 2030

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing prevalence and incidence of hepatocellular carcinoma and liver cirrhosis
  - 5.1.1.2. Rising product development and launch of new direct-acting antiviral medicines
  - 5.1.1.3. Growing awareness and improving healthcare infrastructure in emerging economies
- 5.1.2. Restraints
  - 5.1.2.1. High cost of direct-acting antiviral drugs
- 5.1.3. Opportunities
  - 5.1.3.1. Increasing support from government authorities & social healthcare associations for direct-acting antiviral drug
  - 5.1.3.2. Availability of directly-acting antivirals medicines and strategic collaborations among organizations
- 5.1.4. Challenges
  - 5.1.4.1. Patent expiration of branded direct-acting antiviral
5.2. Market Trends
5.3. Cumulative Impact of COVID-19
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework
5.9. Client Customization

6. Direct-acting Antiviral Drug Market, by Type

6.1. Introduction
6.2. NS3/4A Protease
6.3. NS5A Protein
6.4. NS5B RNA-Dependent RNA polymerase

7. Direct-acting Antiviral Drug Market, by Indication

7.1. Introduction
7.2. Hepatitis C Virus
7.3. HIV Infection/ AIDS
7.4. Influenza
7.5. Prophylaxis

8. Direct-acting Antiviral Drug Market, by Route

8.1. Introduction
8.2. Intravenous
8.3. Oral
8.4. Subcutaneous
8.5. Topical

9. Direct-acting Antiviral Drug Market, by Distribution Channel

9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Drug Store
9.4. Retail Pharmacy

10. Americas Direct-acting Antiviral Drug Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Direct-acting Antiviral Drug Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Direct-acting Antiviral Drug Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

直接作用型抗ウイルス薬市場：タイプ別、適応症別、ルート別、流通チャネル別-2023～2030年の世界予測

Direct-acting Antiviral Drug Market by Type, Indication, Route, Distribution Channel - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

FPNVポジショニング・マトリックス

市場シェア分析

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

第6章 直接作用型抗ウイルス薬市場：タイプ別

第7章 直接作用型抗ウイルス薬市場：適応症別

第8章 直接作用型抗ウイルス薬市場：投与経路別

第9章 直接作用型抗ウイルス薬市場：流通チャネル別

第10章 南北アメリカの直接作用型抗ウイルス薬市場

第11章 アジア太平洋地域の直接作用型抗ウイルス薬市場

第12章 欧州・中東・アフリカの直接作用型抗ウイルス薬市場

第13章 競合情勢

第14章 掲載企業一覧

第15章 付録